Evaluating Myelodysplastic Syndrome Risks in NET Patients Planned for Peptide Radionuclide Therapy

Recruiting now

Conditions studied: Myelodysplastic Syndrome, Acute Myeloid Leukemia

In brief

This is a prospective observational study which aims to identify individuals predisposed to developing myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) could improve patient outcomes in different ways. First, it will enable improved patient selection for PRRT where alternative treatment options are available. Second, understanding the final pathway and how it is modulated by PRRT could allow the design of strategies to halt this process. Third, while it is unknown whether the development of MDS and AML is a late effect of radiopharmaceuticals in general or it is confined to cancer populations or specific radioisotopes will need to be confirmed. Finally, understanding this devastating complication is expected to be the cornerstone towards advancing radiopharmaceuticals' role in the adjuvant setting.

Key facts

Study ID

NCT06510868

Run by

University Health Network, Toronto

People needed

45

Starts

2024-08-01

Expected to finish

2029-06-30

Last updated by the study team

2026-03-05

Who can join

Age: any. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• ECOG 0-3
• Life expectancy > 6 months
• Informed consent and willingness to undergoing serial genetic panel CHIP testing.
• Cohort Specific criteria
• Cohort A: PRRT completed within 5 years of enrolment
• Cohort B: PRRT planned to commence within 4 months of enrolment
• Cohort C: diagnosis of MDS or AML following prior PRRT.

You may not qualify if…

• Unwillingness to provide blood sample and follow up as per protocol

Where it is running

• Princess Margaret Cancer Centre — Toronto, Ontario, Canada (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.